Enanta Pharmaceuticals Inc (ENTA) stock
Close on Nov 13, 2026Market cap $320.09MP/E –Yield –
Earnings
Enanta Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Enanta Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Sep 30, 2026 | Nov 16, 2026Expected | – | – | – | – |
| Q3 FY2026ended Jun 30, 2026 | Aug 10, 2026during market hours | $14.40M | -21.3% | -$0.67 | Release |
| Q2 FY2026ended Mar 31, 2026 | May 11, 2026during market hours | $17.20M | – | -$0.45 | Release |
| Q1 FY2026ended Dec 31, 2025 | Feb 9, 2026during market hours | $18.60M | +9.4% | -$0.42 | Release |
| Q4 FY2025ended Sep 30, 2025 | Nov 17, 2025during market hours | $15.10M | +3.4% | -$0.87 | Release |
| Q3 FY2025ended Jun 30, 2025 | Aug 11, 2025during market hours | $18.30M | +1.7% | -$0.85 | Release |
| Q1 FY2025ended Dec 31, 2024 | Feb 10, 2025during market hours | $17.00M | -5.6% | -$1.05 | Release |
| Q4 FY2024ended Sep 30, 2024 | Nov 25, 2024during market hours | $14.60M | -22.8% | -$1.36 | Release |
| Q3 FY2024ended Jun 30, 2024 | Aug 5, 2024during market hours | $18.00M | -4.8% | -$1.07 | Release |
| Q2 FY2024ended Mar 31, 2024 | May 6, 2024during market hours | $17.10M | -3.9% | -$1.47 | Release |
| Q1 FY2024ended Dec 31, 2023 | Feb 7, 2024during market hours | $18.00M | -23.7% | -$1.58 | Release |
| Q4 FY2023ended Sep 30, 2023 | Nov 20, 2023during market hours | $18.90M | -6.9% | -$1.33 | Release |
| Q3 FY2023ended Jun 30, 2023 | Aug 7, 2023during market hours | $18.90M | -3.1% | -$1.86 | Release |
| Q2 FY2023ended Mar 31, 2023 | May 8, 2023during market hours | $17.80M | -4.8% | -$1.79 | Release |
| Q1 FY2023ended Dec 31, 2022 | Feb 7, 2023during market hours | $23.60M | -14.5% | -$1.39 | Release |
| Q4 FY2022ended Sep 30, 2022 | Nov 21, 2022during market hours | $20.30M | -14.0% | -$1.27 | Release |
| Q3 FY2022ended Jun 30, 2022 | Aug 8, 2022during market hours | $19.50M | – | -$1.53 | Release |
| Q2 FY2022ended Mar 31, 2022 | May 9, 2022during market hours | $18.70M | – | -$1.63 | Release |
| Q1 FY2022ended Dec 31, 2021 | Feb 8, 2022before the open | $27.60M | – | -$1.48 | Release |
| Q4 FY2021ended Sep 30, 2021 | Nov 22, 2021during market hours | $23.60M | – | -$1.22 | Release |
| Q3 FY2021ended Jun 30, 2021 | Aug 5, 2021during market hours | – | – | – | Filing |
| Q2 FY2021ended Mar 31, 2021 | May 6, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Dec 31, 2020 | Feb 8, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Sep 30, 2020 | Nov 23, 2020during market hours | – | – | – | Filing |
| Q3 FY2020ended Jun 30, 2020 | Aug 4, 2020during market hours | – | – | – | Filing |
| Q2 FY2020ended Mar 31, 2020 | May 6, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Enanta Pharmaceuticals guided for has been reported
Guidance history
Every forecast Enanta Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| May 6, 2024 | General and administrative expense | FY2024 | $50.00M – $60.00M | Lowered |
| May 6, 2024 | Research and development expense | FY2024 | $125.00M – $145.00M | Raised |
| Nov 20, 2023 | General and Administrative Expense | FY2024 | $45.00M – $50.00M | Lowered |
| Nov 20, 2023 | Research and Development Expense | FY2024 | $100.00M – $120.00M | New |
| Aug 7, 2023 | General and Administrative Expense | FY2023 | $50.00M – $55.00M | Lowered |
| Aug 7, 2023 | Research and Development Expense | FY2023 | $165.00M – $175.00M | Raised |
| Nov 21, 2022 | General and Administrative Expense | FY2023 | $46.00M – $52.00M | Lowered |
| Nov 21, 2022 | Research and Development Expense | FY2023 | $210.00M – $230.00M | New |
| Nov 22, 2021 | General and Administrative Expense | FY2022 | $35.00M – $41.00M | Lowered |
| Nov 22, 2021 | Research and Development Expense | FY2022 | $150.00M – $170.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Enanta Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for theUpdate
- Update
- Results
- Results
- Results
- Update
- Update
- Update
- Results
- Results
- Results
- Update
- Update
See a number that looks wrong?